214 related articles for article (PubMed ID: 14767499)
1. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant.
Lee CK; Zangari M; Barlogie B; Fassas A; van Rhee F; Thertulien R; Talamo G; Muwalla F; Anaissie E; Hollmig K; Tricot G
Bone Marrow Transplant; 2004 Apr; 33(8):823-8. PubMed ID: 14767499
[TBL] [Abstract][Full Text] [Related]
2. Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure.
Tauro S; Clark FJ; Duncan N; Lipkin G; Richards N; Mahendra P
Bone Marrow Transplant; 2002 Oct; 30(7):471-3. PubMed ID: 12368962
[TBL] [Abstract][Full Text] [Related]
3. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.
Tricot G; Alberts DS; Johnson C; Roe DJ; Dorr RT; Bracy D; Vesole DH; Jagannath S; Meyers R; Barlogie B
Clin Cancer Res; 1996 Jun; 2(6):947-52. PubMed ID: 9816255
[TBL] [Abstract][Full Text] [Related]
4. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.
Raab MS; Breitkreutz I; Hundemer M; Benner A; Klaus J; Hegenbart U; Moehler T; Ho AD; Zeier M; Goldschmidt H
Haematologica; 2006 Nov; 91(11):1555-8. PubMed ID: 17082013
[TBL] [Abstract][Full Text] [Related]
5. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure.
Knudsen LM; Nielsen B; Gimsing P; Geisler C
Eur J Haematol; 2005 Jul; 75(1):27-33. PubMed ID: 15946307
[TBL] [Abstract][Full Text] [Related]
6. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
[TBL] [Abstract][Full Text] [Related]
7. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
Bird JM; Fuge R; Sirohi B; Apperley JF; Hunter A; Snowden J; Mahendra P; Milligan D; Byrne J; Littlewood T; Fegan C; McQuaker G; Pagliuca A; Johnson P; Rahemtulla A; Morris C; Marks DI;
Br J Haematol; 2006 Aug; 134(4):385-90. PubMed ID: 16822294
[TBL] [Abstract][Full Text] [Related]
8. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
[TBL] [Abstract][Full Text] [Related]
9. Renal failure in multiple myeloma. A study of the presenting findings, response to treatment and prognosis in 26 patients.
Cavo M; Baccarani M; Galieni P; Gobbi M; Tura S
Nouv Rev Fr Hematol (1978); 1986; 28(3):147-52. PubMed ID: 3748798
[TBL] [Abstract][Full Text] [Related]
10. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
12. [Autologous transplantation of peripheral hematopoietic cells in a patient with multiple myeloma and renal insufficiency].
Krejcí M; Doubek M; Adam Z; Hájek R; Vorlícek J; Mayer J
Vnitr Lek; 1997 Nov; 43(11):756-8. PubMed ID: 9650509
[TBL] [Abstract][Full Text] [Related]
13. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute renal failure due to myeloma kidney.
Bear RA; Cole EH; Lang A; Johnson M
Can Med Assoc J; 1980 Oct; 123(8):750-3. PubMed ID: 7004618
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
16. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
17. [Survival of myeloma patients treated with dialysis].
Martín Reyes G; Valera A; Frutos MA; Ramos B; Ordóñez V; López de Novales E
Nefrologia; 2003; 23(2):131-6. PubMed ID: 12778877
[TBL] [Abstract][Full Text] [Related]
18. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.
Qazilbash MH; Saliba RM; Hosing C; Mendoza F; Qureshi SR; Weber DM; Wang M; Flosser T; Couriel DR; De Lima M; Kebriaei P; Popat U; Alousi AM; Champlin RE; Giralt SA
Bone Marrow Transplant; 2007 Mar; 39(5):279-83. PubMed ID: 17262062
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma in end-stage renal disease.
Penfield JG
Semin Dial; 2006; 19(4):329-34. PubMed ID: 16893412
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
